Acambis offloads vaccine assets

A mere three years after it acquired Berna Products Corp
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
CAMBRIDGE, U.K.—A mere three years after it acquired Berna Products Corp., Acambis has sold the company to Crucell NV for $16.5 million. Berna sells and distributes Vivotif, an oral typhoid vaccine, in North America under a licensing and distribution agreement it signed with Berna Biotech AG, which was acquired by Crucell earlier this year. The distribution agreement was scheduled to end in 2010.
 
"Berna Products is no longer a strategic asset and its sale today crystallizes $16.5 million of value and cash in the short term," said Acambis CEO Gordon Cameron. "Together with the recently announced $19-million ARILVAX settlement and near-term revenues from the ACAM2000 U.S. government $30-million order, this deal further strengthens our financial position as we drive toward our goal of building a high-value product pipeline."
 
The sale includes operations in Miami and Canada, employing 15 people, and comes as a competitive product to Vivotif re-enters the market.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue